Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 530

1.

Identification of salivary components that induce transition of hyphae to yeast in Candida albicans.

Leito JT, Ligtenberg AJ, Nazmi K, Veerman EC.

FEMS Yeast Res. 2009 Oct;9(7):1102-10. doi: 10.1111/j.1567-1364.2009.00575.x. Epub 2009 Sep 7.

2.

Resveratrol impaired the morphological transition of Candida albicans under various hyphae-inducing conditions.

Okamoto-Shibayama K, Sato Y, Azuma T.

J Microbiol Biotechnol. 2010 May;20(5):942-5.

3.

Valinomycin affects the morphology of Candida albicans.

Watanabe H, Azuma M, Igarashi K, Ooshima H.

J Antibiot (Tokyo). 2005 Dec;58(12):753-8.

PMID:
16506692
4.

Effect of saliva composition on growth of Candida albicans and Torulopsis glabrata.

Lenander-Lumikari M, Johansson I.

Oral Microbiol Immunol. 1995 Aug;10(4):233-40.

PMID:
8602336
5.

Adhesion of Candida albicans, but not Candida krusei, to salivary statherin and mimicking host molecules.

Johansson I, Bratt P, Hay DI, Schluckebier S, Strömberg N.

Oral Microbiol Immunol. 2000 Apr;15(2):112-8.

PMID:
11155174
6.

The in vitro proteolytic and saccharolytic activity of Candida species cultured in human saliva.

Samaranayake YH, MacFarlane TW, Samaranayake LP, Aitchison T.

Oral Microbiol Immunol. 1994 Aug;9(4):229-35.

PMID:
7478763
7.

2-dodecanol (decyl methyl carbinol) inhibits hyphal formation and SIR2 expression in C. albicans.

Lim CS, Wong WF, Rosli R, Ng KP, Seow HF, Chong PP.

J Basic Microbiol. 2009 Dec;49(6):579-83. doi: 10.1002/jobm.200900035.

PMID:
19810039
8.

The formation of hyphae of Candida albicans induced by cyclodextrins.

Fekete-Forgács K, Szabó E, Lenkey B.

Mycoses. 1997 Dec;40(11-12):451-3.

PMID:
9470411
9.

Proteolytic activity of Candida albicans: action on human salivary proteins.

Germaine GR, Tellefson LM, Johnson GL.

Infect Immun. 1978 Dec;22(3):861-6.

10.

Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation.

Murzyn A, Krasowska A, Stefanowicz P, Dziadkowiec D, Łukaszewicz M.

PLoS One. 2010 Aug 10;5(8):e12050. doi: 10.1371/journal.pone.0012050.

11.

Salivary anti-candidal assays.

Santarpia RP 3rd, Xu L, Lal K, Pollock JJ.

Oral Microbiol Immunol. 1992 Feb;7(1):38-43.

PMID:
1528623
12.

Streptococcus mutans competence-stimulating peptide inhibits Candida albicans hypha formation.

Jarosz LM, Deng DM, van der Mei HC, Crielaard W, Krom BP.

Eukaryot Cell. 2009 Nov;8(11):1658-64. doi: 10.1128/EC.00070-09. Epub 2009 Aug 28.

13.

The influence of morphological variation on Candida albicans adhesion to denture acrylic in vitro.

Vasilas A, Molina L, Hoffman M, Haidaris CG.

Arch Oral Biol. 1992 Aug;37(8):613-22.

PMID:
1514934
14.

Identification of inhibitors of yeast-to-hyphae transition in Candida albicans by a reporter screening assay.

Heintz-Buschart A, Eickhoff H, Hohn E, Bilitewski U.

J Biotechnol. 2013 Mar 10;164(1):137-42. doi: 10.1016/j.jbiotec.2012.12.004. Epub 2012 Dec 20.

PMID:
23262131
15.

Inhibitory activity of thymol against the formation and viability of Candida albicans hyphae.

Braga PC, Alfieri M, Culici M, Dal Sasso M.

Mycoses. 2007 Nov;50(6):502-6.

PMID:
17944714
16.

Candida albicans PHO81 is required for the inhibition of hyphal development by farnesoic acid.

Chung SC, Kim TI, Ahn CH, Shin J, Oh KB.

FEBS Lett. 2010 Nov 19;584(22):4639-45. doi: 10.1016/j.febslet.2010.10.026. Epub 2010 Oct 21.

17.

Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism.

Kim S, Kim E, Shin DS, Kang H, Oh KB.

Bioorg Med Chem Lett. 2002 Mar 25;12(6):895-8.

PMID:
11958988
19.

Antagonistic interplay of Swi1 and Tup1 on filamentous growth of Candida albicans.

Mao X, Li Y, Wang H, Cao F, Chen J.

FEMS Microbiol Lett. 2008 Aug;285(2):233-41. doi: 10.1111/j.1574-6968.2008.01236.x. Epub 2008 Jun 28.

20.

LAAE-14, a new anti-inflammatory drug, increases the survival of Candida albicans-inoculated mice.

Lucas R, Villamón E, Payá M, Alves M, del Olmo E, Gozalbo D, Gil ML.

FEMS Immunol Med Microbiol. 2004 Apr 9;40(3):239-42.

Supplemental Content

Support Center